{"id":"https://openalex.org/W3132020489","doi":"https://doi.org/10.1089/jop.2020.0071","title":"Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys","display_name":"Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys","publication_year":2021,"publication_date":"2021-02-18","ids":{"openalex":"https://openalex.org/W3132020489","doi":"https://doi.org/10.1089/jop.2020.0071","mag":"3132020489","pmid":"https://pubmed.ncbi.nlm.nih.gov/33600237"},"language":"en","primary_location":{"id":"doi:10.1089/jop.2020.0071","doi":"https://doi.org/10.1089/jop.2020.0071","is_oa":true,"landing_page_url":"https://doi.org/10.1089/jop.2020.0071","pdf_url":null,"source":{"id":"https://openalex.org/S192126995","display_name":"Journal of Ocular Pharmacology and Therapeutics","issn_l":"1080-7683","issn":["1080-7683","1557-7732","8756-3320"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Ocular Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1089/jop.2020.0071","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032129452","display_name":"Masahiro Fuwa","orcid":"https://orcid.org/0000-0002-7958-762X","observed_orcids":["https://orcid.org/0000-0002-7958-762X"]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Masahiro Fuwa","raw_affiliation_strings":["Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042354585","display_name":"Atsushi Shimazaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Atsushi Shimazaki","raw_affiliation_strings":["Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051725756","display_name":"Noriko Odani\u2010Kawabata","orcid":"https://orcid.org/0000-0001-9776-6077","observed_orcids":["https://orcid.org/0000-0001-9776-6077"]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]},{"id":"https://openalex.org/I4210099140","display_name":"Santen (United States)","ror":"https://ror.org/0108v8438","country_code":"US","type":"company","lineage":["https://openalex.org/I149737975","https://openalex.org/I4210099140"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Noriko Odani-Kawabata","raw_affiliation_strings":["Product Development Division, Santen Inc., Emeryville, California, USA","Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development Division, Santen Inc., Emeryville, California, USA","institution_ids":["https://openalex.org/I4210099140"]},{"raw_affiliation_string":"Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038904871","display_name":"Tomoko Kirihara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Kirihara","raw_affiliation_strings":["Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Osaka, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105544981","display_name":"Takazumi Taniguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takazumi Taniguchi","raw_affiliation_strings":["Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Osaka, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088264632","display_name":"Ryo Iwamura","orcid":"https://orcid.org/0000-0002-0598-1755","observed_orcids":["https://orcid.org/0000-0002-0598-1755"]},"institutions":[{"id":"https://openalex.org/I861488341","display_name":"Ube (Japan)","ror":"https://ror.org/05xhmzx41","country_code":"JP","type":"company","lineage":["https://openalex.org/I861488341"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryo Iwamura","raw_affiliation_strings":["Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan","institution_ids":["https://openalex.org/I861488341"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109530024","display_name":"Kenji Yoneda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I861488341","display_name":"Ube (Japan)","ror":"https://ror.org/05xhmzx41","country_code":"JP","type":"company","lineage":["https://openalex.org/I861488341"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Yoneda","raw_affiliation_strings":["Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan","institution_ids":["https://openalex.org/I861488341"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000103541","display_name":"Masatomo Kato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masatomo Kato","raw_affiliation_strings":["Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kenji Morishima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149737975","display_name":"Santen (Japan)","ror":"https://ror.org/032msy923","country_code":"JP","type":"company","lineage":["https://openalex.org/I149737975"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Morishima","raw_affiliation_strings":["Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan","institution_ids":["https://openalex.org/I149737975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109417546","display_name":"Naveed K. Shams","orcid":"https://orcid.org/0009-0001-8484-6032","observed_orcids":["https://orcid.org/0009-0001-8484-6032"]},"institutions":[{"id":"https://openalex.org/I4210099140","display_name":"Santen (United States)","ror":"https://ror.org/0108v8438","country_code":"US","type":"company","lineage":["https://openalex.org/I149737975","https://openalex.org/I4210099140"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naveed K. Shams","raw_affiliation_strings":["Ophthalmology Innovation Center, Santen, Inc., Emeryville, California, USA","Product Development Division, Santen Inc., Emeryville, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ophthalmology Innovation Center, Santen, Inc., Emeryville, California, USA","institution_ids":["https://openalex.org/I4210099140"]},{"raw_affiliation_string":"Product Development Division, Santen Inc., Emeryville, California, USA","institution_ids":["https://openalex.org/I4210099140"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5032129452"],"corresponding_institution_ids":["https://openalex.org/I149737975"],"apc_list":null,"apc_paid":null,"fwci":3.8288,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.94109645,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"37","issue":"4","first_page":"223","last_page":"229"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11291","display_name":"Intraocular Surgery and Lenses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ep2-receptor-agonist","display_name":"EP2 receptor agonist","score":0.9670000076293945},{"id":"https://openalex.org/keywords/intraocular-pressure-reduction","display_name":"intraocular pressure reduction","score":0.7730000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6299999952316284},{"id":"https://openalex.org/keywords/glaucoma-medications","display_name":"glaucoma medications","score":0.9850000143051147},{"id":"https://openalex.org/keywords/timolol","display_name":"timolol","score":0.7889999747276306},{"id":"https://openalex.org/keywords/brinzolamide","display_name":"brinzolamide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/netarsudil","display_name":"netarsudil","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ripasudil","display_name":"ripasudil","score":0.9959999918937683},{"id":"https://openalex.org/keywords/brimonidine","display_name":"brimonidine","score":1.0},{"id":"https://openalex.org/keywords/ocular-hypotensive-agents","display_name":"ocular hypotensive agents","score":0.7990000247955322},{"id":"https://openalex.org/keywords/glaucoma","display_name":"glaucoma","score":0.7239999771118164},{"id":"https://openalex.org/keywords/cynomolgus-monkeys","display_name":"Macaca fascicularis","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C2781092963","wikidata":"https://www.wikidata.org/wiki/Q650050","display_name":"Intraocular pressure","level":2,"score":0.7882287502288818},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6735159158706665},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6687765121459961},{"id":"https://openalex.org/C2778073030","wikidata":"https://www.wikidata.org/wiki/Q413994","display_name":"Timolol","level":3,"score":0.6472854018211365},{"id":"https://openalex.org/C2776740260","wikidata":"https://www.wikidata.org/wiki/Q634959","display_name":"Latanoprost","level":3,"score":0.6196715831756592},{"id":"https://openalex.org/C2776521421","wikidata":"https://www.wikidata.org/wiki/Q9294051","display_name":"Ocular hypertension","level":3,"score":0.5695854425430298},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5615519881248474},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.49858832359313965},{"id":"https://openalex.org/C2776727336","wikidata":"https://www.wikidata.org/wiki/Q415401","display_name":"Dorzolamide","level":4,"score":0.47203385829925537},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3794004023075104},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2695015072822571},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19745787978172302}],"mesh":[{"descriptor_ui":"D000287","descriptor_name":"Administration, Topical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000319","descriptor_name":"Adrenergic beta-Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002257","descriptor_name":"Carbonic Anhydrase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003243","descriptor_name":"Consciousness","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D005901","descriptor_name":"Glaucoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007429","descriptor_name":"Intraocular Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008252","descriptor_name":"Macaca fascicularis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009883","descriptor_name":"Ophthalmic Solutions","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014065","descriptor_name":"Tonometry, Ocular","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054460","descriptor_name":"rho-Associated Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D054460","descriptor_name":"rho-Associated Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058307","descriptor_name":"Receptors, Prostaglandin E, EP2 Subtype","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D058647","descriptor_name":"Adrenergic alpha-2 Receptor Agonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1089/jop.2020.0071","doi":"https://doi.org/10.1089/jop.2020.0071","is_oa":true,"landing_page_url":"https://doi.org/10.1089/jop.2020.0071","pdf_url":null,"source":{"id":"https://openalex.org/S192126995","display_name":"Journal of Ocular Pharmacology and Therapeutics","issn_l":"1080-7683","issn":["1080-7683","1557-7732","8756-3320"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Ocular Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:33600237","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33600237","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1089/jop.2020.0071","doi":"https://doi.org/10.1089/jop.2020.0071","is_oa":true,"landing_page_url":"https://doi.org/10.1089/jop.2020.0071","pdf_url":null,"source":{"id":"https://openalex.org/S192126995","display_name":"Journal of Ocular Pharmacology and Therapeutics","issn_l":"1080-7683","issn":["1080-7683","1557-7732","8756-3320"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Ocular Pharmacology and Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1984673463","https://openalex.org/W1985644715","https://openalex.org/W2012408175","https://openalex.org/W2025595981","https://openalex.org/W2041847148","https://openalex.org/W2049570329","https://openalex.org/W2051572319","https://openalex.org/W2057266151","https://openalex.org/W2064079687","https://openalex.org/W2078255196","https://openalex.org/W2086321796","https://openalex.org/W2118359262","https://openalex.org/W2151014103","https://openalex.org/W2153367682","https://openalex.org/W2159375732","https://openalex.org/W2213028454","https://openalex.org/W2258579859","https://openalex.org/W2418704175","https://openalex.org/W2625521663","https://openalex.org/W2729341911","https://openalex.org/W2783861782","https://openalex.org/W2827702279","https://openalex.org/W2856071374","https://openalex.org/W2918259642","https://openalex.org/W2998880617","https://openalex.org/W3024912093","https://openalex.org/W3035005545","https://openalex.org/W3036639088","https://openalex.org/W4206485229","https://openalex.org/W4240661191"],"related_works":["https://openalex.org/W2992790282","https://openalex.org/W2783861782","https://openalex.org/W3017005220","https://openalex.org/W2738982098","https://openalex.org/W4390474309","https://openalex.org/W4288684464","https://openalex.org/W2856071374","https://openalex.org/W4224608775","https://openalex.org/W3197069414","https://openalex.org/W3204571829"],"abstract_inverted_index":{"Purpose:":[0],"To":[1],"investigate":[2],"the":[3,93,118,151,161,175],"intraocular":[4],"pressure":[5],"(IOP)-lowering":[6],"effects":[7,110,185],"of":[8,90,111,117,132,150,158,219,223],"omidenepag":[9],"isopropyl":[10],"(OMDI),":[11],"a":[12,22],"potent":[13],"and":[14,77,82,126,206],"highly":[15],"selective":[16],"prostanoid":[17],"EP2":[18],"receptor":[19],"agonist,":[20],"as":[21],"potential":[23],"first-line":[24],"ocular":[25,36],"hypotensive":[26],"agent":[27],"when":[28,186,225],"combined":[29,59],"with":[30,60,115,148,160,190],"existing":[31],"antiglaucoma":[32,120,153,192],"agents":[33,121,154,163],"in":[34,96,174,188],"conscious":[35,46],"normotensive":[37],"monkeys.":[38],"Methods:":[39],"Male":[40],"cynomolgus":[41],"monkeys":[42],"were":[43,128,144],"examined":[44],"under":[45],"conditions.":[47],"OMDI":[48,91,112,133,159,181,213],"ophthalmic":[49,62],"solution":[50],"alone":[51],"was":[52,70,74],"topically":[53],"applied":[54],"to":[55,92,140,167],"an":[56],"eye":[57,69,94],"or":[58,172],"other":[61],"solutions":[63],"at":[64,78,104],"5-min":[65],"intervals.":[66],"The":[67,108],"contralateral":[68],"left":[71],"untreated.":[72],"IOP":[73,99,138],"measured":[75],"before":[76],"2,":[79],"4,":[80],"6,":[81],"8":[83],"h":[84],"after":[85],"instillation.":[86],"Results:":[87],"Topical":[88],"application":[89],"resulted":[95],"statistically":[97,145],"significant":[98,146],"reduction,":[100],"which":[101],"lasted":[102],"for":[103],"least":[105],"6":[106],"h.":[107],"IOP-lowering":[109,184],"concomitantly":[113],"administered":[114,187],"any":[116],"tested":[119,152,162],"(timolol,":[122],"brinzolamide,":[123],"netarsudil,":[124],"ripasudil,":[125],"brimonidine)":[127],"greater":[129],"than":[130],"those":[131,149],"alone.":[134,155],"Furthermore,":[135],"these":[136],"enhanced":[137],"responses":[139],"their":[141],"concomitant":[142],"use":[143],"compared":[147],"Any":[156],"combination":[157,189,226],"did":[164],"not":[165],"lead":[166],"serious":[168],"abnormalities":[169],"either":[170],"systemically":[171],"locally":[173],"eye.":[176],"Conclusions:":[177],"We":[178],"demonstrated":[179],"that":[180,212],"has":[182],"additive":[183],"various":[191],"agents,":[193],"namely,":[194],"\u03b2-adrenergic":[195],"antagonist,":[196],"carbonic":[197],"anhydrase":[198],"inhibitor,":[199],"Rho-associated":[200],"coiled-coil":[201],"containing":[202],"protein":[203],"kinase":[204],"inhibitors,":[205],"\u03b12-adrenergic":[207],"agonist.":[208],"These":[209],"results":[210],"suggest":[211],"provides":[214],"additional":[215],"clinical":[216],"benefits":[217],"because":[218],"its":[220],"unique":[221],"mechanisms":[222],"action":[224],"therapy":[227],"is":[228],"required.":[229]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-03-01T00:00:00"}